News & Updates
Filter by Specialty:
Real-world data back CV safety of JAK inhibitors
Two real-world studies presented at EULAR 2023 reflected the cardiovascular (CV) safety of Janus kinase inhibitors (JAKi*) in patients with rheumatoid arthritis (RA).
Real-world data back CV safety of JAK inhibitors
28 Jun 2023
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
Treatment with sacituzumab govitecan (SG) demonstrates clinically meaningful overall survival (OS) over single-agent chemotherapy in patients with pretreated, endocrine-resistant, hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC), as confirmed by the final OS analysis from the TROPiCS-02 study, presented at ASCO 2023.
Sacituzumab govitecan proven safe, effective in metastatic breast cancer
26 Jun 2023
Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease
Use of pembrolizumab is well tolerated in nonsmall cell lung cancer (NSCLC) patients with previous autoimmune diseases, with a nonsignificant trend toward improved outcomes, reports a study.
Pembrolizumab well tolerated, effective in NSCLC with autoimmune disease
25 Jun 2023
Nivolumab-AVD superior to brentuximab vedotin-AVD for advanced stage Hodgkin lymphoma
Treatment with nivolumab (N) plus doxorubicin, vinblastine, and dacarbazine (AVD) leads to improved progression-free survival (PFS) relative to brentuximab vedotin (BV) plus AVD in patients with advanced stage classic Hodgkin lymphoma (HL), according to the results of the SWOG S1826 study, which was presented at the recent ASCO 2023.